Aurigene Oncology receives nod for Phase 2 clinical trial for Ribrecabtagene autoleucel

Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy's Laboratories has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study - India's first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma.